Researchers at the Icahn School of Medicine at Mount Sinai have received more than $3 million from the National Institutes of Health for a five-year study of advanced MRI methods that may help locate the brain regions causing seizures in people with drug-resistant epilepsy. The team wants to know whether these methods can improve diagnosis and inform treatment planning.
Epilepsy is a neurological disorder marked by recurrent seizures. Medication controls them for many people, but some continue to have seizures despite treatment. For eligible patients, surgery may improve seizure control or stop seizures altogether, and surgical planning depends partly on identifying the brain tissue where seizures begin. That task is difficult when standard MRI scans show no clear target, which is often the case.
The study will test two complementary approaches. Magnetic resonance elastography, or MRE, measures tissue properties including stiffness, and advanced MRI methods also measure blood flow in the brain. The researchers hope these measurements will reveal differences between seizure-causing regions and nearby tissue that routine scans miss. The idea grew out of conversations with neurosurgeons, who sometimes notice that tissue where seizures begin feels firmer during epilepsy operations.
The study will enroll 100 people with drug-resistant epilepsy, half with visible brain lesions on MRI and half without, along with 50 healthy volunteers. Participants will be scanned on 7-tesla and/or 3-tesla machines, and researchers will analyze blood samples for markers associated with gliosis, a glial cell response that can follow brain injury or disease. Where available, imaging results will be compared with EEG recordings, tissue removed during surgery, and clinical outcomes to assess how reliably the MRI measurements identify seizure-causing regions.
If the approach holds up, the team hopes to run a larger clinical trial testing whether adding these measurements to patient care improves treatment decisions and outcomes, and they also want to explore use in children. Principal investigator Priti Balchandani, PhD, framed the long-term goal as imaging that gives clinicians a clearer picture of where seizures originate.